Top

Journal of Cardiovascular Translational Research

Published in:

09-08-2023 | Sudden Cardiac Death | Original Article

Metabolomics Profiling Predicts Ventricular Arrhythmia in Patients with an Implantable Cardioverter Defibrillator

Authors: Shengwen Yang, Junhan Zhao, Xi Liu, Jing Wang, Min Gu, Chi Cai, Hongxia Niu, Liang Chen, Wei Hua

Published in: Journal of Cardiovascular Translational Research | Issue 1/2024

Abstract

Implantable cardioverter defibrillators (ICDs) reduce sudden cardiac death (SCD) when patients experience life-threatening ventricular arrhythmias (LTVA). However, current strategies determining ICD patient selection and risk stratification are inefficient. We used metabolomics to assess whether dysregulated metabolites are associated with LTVA and identify potential biomarkers. Baseline plasma samples were collected from 72 patients receiving ICDs. Over a median follow-up of 524.0 days (range 239.0–705.5), LTVA occurred in 23 (31.9%) patients (22 effective ICD treatments and 1 SCD). After confounding risk factors adjustment for age, smoking, secondary prevention, and creatine kinase MB, 23 metabolites were significantly associated with LTVA. Pathway analysis revealed LTVA associations with disrupted metabolism of glycine, serine, threonine, and branched chain amino acids. Pathway enrichment analysis identified a panel of 6 metabolites that potentially predicted LTVA, with an area under the receiver operating characteristic curve of 0.8. Future studies are necessary on biological mechanisms and potential clinical use.

Graphical abstract

Available only for authorised users

Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation. 2008;118(14):1497–518.CrossRefPubMed

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):e91–e220. https://doi.org/10.1016/j.jacc.2017.10.054.CrossRefPubMed

Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51(21):e1–62. https://doi.org/10.1016/j.jacc.2008.02.032.CrossRefPubMed

Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37. https://doi.org/10.1056/NEJMoa043399.CrossRefPubMed

Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83. https://doi.org/10.1056/NEJMoa013474.CrossRefPubMed

Zwanziger J, Hall WJ, Dick AW, Zhao H, Mushlin AI, Hahn RM, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47(11):2310–8. https://doi.org/10.1016/j.jacc.2006.03.032.CrossRefPubMed

Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007;50(12):1150–7. https://doi.org/10.1016/j.jacc.2007.04.095.CrossRefPubMed

Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51(3):288–96. https://doi.org/10.1016/j.jacc.2007.08.058.CrossRefPubMed

Goldberger JJ, Buxton AE, Cain M, Costantini O, Exner DV, Knight BP, et al. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation. 2011;123(21):2423–30. https://doi.org/10.1161/CIRCULATIONAHA.110.959734.CrossRefPubMed

10.

Griffin JL, Atherton H, Shockcor J, Atzori L. Metabolomics as a tool for cardiac research. Nat Rev Cardiol. 2011;8(11):630–43. https://doi.org/10.1038/nrcardio.2011.138.CrossRefPubMed

11.

Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation. 2012;126(9):1110–20. https://doi.org/10.1161/CIRCULATIONAHA.111.060368.CrossRefPubMedPubMedCentral

12.

Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17(7):451–9. https://doi.org/10.1038/nrm.2016.25.CrossRefPubMedPubMedCentral

13.

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):1677–749. https://doi.org/10.1016/j.jacc.2017.10.053.CrossRefPubMed

14.

Zhao J, Yang S, Jing R, Jin H, Hu Y, Wang J, et al. Plasma metabolomic profiles differentiate patients with dilated cardiomyopathy and ischemic cardiomyopathy. Front Cardiovasc Med. 2020;7:597546. https://doi.org/10.3389/fcvm.2020.597546.CrossRefPubMedPubMedCentral

15.

Chong J, Wishart DS, Xia J. Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. Curr Protoc Bioinformatics. 2019;68(1):e86. https://doi.org/10.1002/cpbi.86.CrossRefPubMed

16.

Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221–30. https://doi.org/10.1056/NEJMoa1608029.CrossRefPubMed

17.

Barbier P, Mirea O, Cefalù C, Maltagliati A, Savioli G, Guglielmo M. Reliability and feasibility of longitudinal AFI global and segmental strain compared with 2D left ventricular volumes and ejection fraction: intra- and inter-operator, test-retest, and inter-cycle reproducibility. Eur Heart J Cardiovasc Imaging. 2015;16(6):642–52. https://doi.org/10.1093/ehjci/jeu274.CrossRefPubMed

18.

Barsheshet A, Moss AJ, Huang DT, McNitt S, Zareba W, Goldenberg I. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol. 2012;59(23):2075–9. https://doi.org/10.1016/j.jacc.2012.02.036.CrossRefPubMed

19.

Zhang S, Ching C-K, Huang D, Liu Y-B, Rodriguez-Guerrero DA, Hussin A, et al. Utilization of implantable cardioverter-defibrillators for the prevention of sudden cardiac death in emerging countries: improve SCA clinical trial. Heart Rhythm. 2020;17(3):468–75. https://doi.org/10.1016/j.hrthm.2019.09.023.CrossRefPubMed

20.

Martínez Y, Li X, Liu G, Bin P, Yan W, Más D, et al. The role of methionine on metabolism, oxidative stress, and diseases. Amino Acids. 2017;49(12):2091–8. https://doi.org/10.1007/s00726-017-2494-2.CrossRefPubMed

21.

Sanderson SM, Gao X, Dai Z, Locasale JW. Methionine metabolism in health and cancer: a nexus of diet and precision medicine. Nat Rev Cancer. 2019;19(11):625–37. https://doi.org/10.1038/s41568-019-0187-8.CrossRefPubMed

22.

Lundberg P, Dudman NP, Kuchel PW, Wilcken DE. 1H NMR determination of urinary betaine in patients with premature vascular disease and mild homocysteinemia. Clin Chem. 1995;41(2):275–83.CrossRefPubMed

23.

Lever M, Atkinson W, Slow S, Chambers ST, George PM. Plasma and urine betaine and dimethylglycine variation in healthy young male subjects. Clin Biochem. 2009;42(7–8):706–12. https://doi.org/10.1016/j.clinbiochem.2009.02.001.CrossRefPubMed

24.

Barter PJ, Rye K-A. Homocysteine and cardiovascular disease: is HDL the link? Circ Res. 2006;99(6):565–6. https://doi.org/10.1161/01.RES.0000243583.39694.1f.CrossRefPubMed

25.

Organ CL, Otsuka H, Bhushan S, Wang Z, Bradley J, Trivedi R, et al. Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail. 2016;9(1):e002314. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002314.CrossRefPubMed

26.

Svingen GFT, Ueland PM, Pedersen EKR, Schartum-Hansen H, Seifert R, Ebbing M, et al. Plasma dimethylglycine and risk of incident acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol. 2013;33(8):2041–8. https://doi.org/10.1161/ATVBAHA.113.301714.CrossRefPubMed

27.

Lever M, George PM, Elmslie JL, Atkinson W, Slow S, Molyneux SL, et al. Betaine and secondary events in an acute coronary syndrome cohort. PLoS One. 2012;7(5):e37883. https://doi.org/10.1371/journal.pone.0037883.ADSCrossRefPubMedPubMedCentral

28.

Blüml S. In vivo quantitation of cerebral metabolite concentrations using natural abundance 13C MRS at 1.5 T. J Magnet Resonance (San Diego, Calif.: 1997). 1999;136(2):219–25. https://doi.org/10.1006/jmre.1998.1618.CrossRef

29.

Sahin I, Alkan A, Keskin L, Cikim A, Karakas HM, Firat AK, Sigirci A. Evaluation of in vivo cerebral metabolism on proton magnetic resonance spectroscopy in patients with impaired glucose tolerance and type 2 diabetes mellitus. J Diabetes Complicat. 2008;22(4):254–60. https://doi.org/10.1016/j.jdiacomp.2007.03.007.CrossRef

30.

Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AMA. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol. 2007;81(2):89–131. https://doi.org/10.1016/j.pneurobio.2006.12.003.CrossRefPubMedPubMedCentral

31.

Schuff N, Meyerhoff DJ, Mueller S, Chao L, Sacrey DT, Laxer K, Weiner MW. N-acetylaspartate as a marker of neuronal injury in neurodegenerative disease. Adv Exp Med Biol. 2006;576:241–62; discussion 361-363. https://doi.org/10.1007/0-387-30172-0_17.CrossRefPubMedPubMedCentral

32.

Daniele G, Campi B, Saba A, Codini S, Ciccarone A, Giusti L, et al. Plasma N-acetylaspartate is related to age, obesity, and glucose metabolism: effects of antidiabetic treatment and bariatric surgery. Front Endocrinol. 2020;11:216. https://doi.org/10.3389/fendo.2020.00216.CrossRef

33.

Lee CW, Lee JH, Lim TH, Yang HS, Hong MK, Song JK, et al. Prognostic significance of cerebral metabolic abnormalities in patients with congestive heart failure. Circulation. 2001;103(23):2784–7. https://doi.org/10.1161/01.cir.103.23.2784.CrossRefPubMed

34.

Lee CW, Lee JH, Kim JJ, Park SW, Hong MK, Kim ST, et al. Cerebral metabolic abnormalities in congestive heart failure detected by proton magnetic resonance spectroscopy. J Am Coll Cardiol. 1999;33(5):1196–202. https://doi.org/10.1016/s0735-1097(98)00701-3.CrossRefPubMed

35.

Makide K, Kitamura H, Sato Y, Okutani M, Aoki J. Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. Prostaglandins Other Lipid Mediat. 2009;89(3–4):135–9. https://doi.org/10.1016/j.prostaglandins.2009.04.009.CrossRefPubMed

36.

Herrmann J, Mannheim D, Wohlert C, Versari D, Meyer FB, McConnell JP, et al. Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome. Eur Heart J. 2009;30(23):2930–8. https://doi.org/10.1093/eurheartj/ehp309.CrossRefPubMedPubMedCentral

37.

Park KS, Kim M-K, Im D-S, Bae Y-S. Effect of lysophosphatidylglycerol on several signaling molecules in OVCAR-3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor. Biochem Pharmacol. 2007;73(5):675–81. https://doi.org/10.1016/j.bcp.2006.11.010.CrossRefPubMed

38.

Walsh SK, Hector EE, Andréasson A-C, Jönsson-Rylander A-C, Wainwright CL. GPR55 deletion in mice leads to age-related ventricular dysfunction and impaired adrenoceptor-mediated inotropic responses. PLoS One. 2014;9(9):e108999. https://doi.org/10.1371/journal.pone.0108999.ADSCrossRefPubMedPubMedCentral

39.

Zegarlińska J, Piaścik M, Sikorski AF, Czogalla A. Phosphatidic acid - a simple phospholipid with multiple faces. Acta Biochim Pol. 2018;65(2):163–71. https://doi.org/10.18388/abp.2018_2592.CrossRefPubMed

40.

Takahashi H, Takeishi Y, Seidler T, Arimoto T, Akiyama H, Hozumi Y, et al. Adenovirus-mediated overexpression of diacylglycerol kinase-zeta inhibits endothelin-1-induced cardiomyocyte hypertrophy. Circulation. 2005;111(12):1510–6. https://doi.org/10.1161/01.CIR.0000159339.00703.22.CrossRefPubMed

41.

Arimoto T, Takeishi Y, Takahashi H, Shishido T, Niizeki T, Koyama Y, et al. Cardiac-specific overexpression of diacylglycerol kinase zeta prevents Gq protein-coupled receptor agonist-induced cardiac hypertrophy in transgenic mice. Circulation. 2006;113(1):60–6. https://doi.org/10.1161/CIRCULATIONAHA.105.560771.CrossRefPubMed

42.

Dhalla NS, Xu YJ, Sheu SS, Tappia PS, Panagia V. Phosphatidic acid: a potential signal transducer for cardiac hypertrophy. J Mol Cell Cardiol. 1997;29(11):2865–71. https://doi.org/10.1006/jmcc.1997.0522.CrossRefPubMed

43.

Waugh M. Measuring phosphatidylinositol generation on biological membranes. Methods Mol Biol. 2016;1376:239–46. https://doi.org/10.1007/978-1-4939-3170-5_20.CrossRefPubMed

44.

Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606–19. https://doi.org/10.1038/nrg1879.CrossRefPubMed

45.

Ghigo A, Laffargue M, Li M, Hirsch E. PI3K and calcium signaling in cardiovascular disease. Circ Res. 2017;121(3):282–92. https://doi.org/10.1161/CIRCRESAHA.117.310183.CrossRefPubMed

Title: Metabolomics Profiling Predicts Ventricular Arrhythmia in Patients with an Implantable Cardioverter Defibrillator
Authors: Shengwen Yang
Junhan Zhao
Xi Liu
Jing Wang
Min Gu
Chi Cai
Hongxia Niu
Liang Chen
Wei Hua
Publication date: 09-08-2023
Publisher: Springer US
Keywords: Sudden Cardiac Death
ICD Implantation
Implantable Cardioverter Defibrillator
Implantable Cardioverter Defibrillator
ICD Implantation
ICD Implantation
Published in: Journal of Cardiovascular Translational Research / Issue 1/2024
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-023-10413-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Metabolomics Profiling Predicts Ventricular Arrhythmia in Patients with an Implantable Cardioverter Defibrillator

Abstract

Graphical abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Graphical abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

HIPK1: a New Druggable Kinase Target for Treating Pathological Cardiac Hypertrophy

Cardiac Metabolism, Reprogramming, and Diseases

The Characteristics of Macrophage Heterogeneity in Atherosclerotic Aortas

The Fragmented QRS Complex in Lead V1: Time for an Update of the Athlete’s ECG?

FAM3A Deficiency − Induced Mitochondrial Dysfunction Underlies Post-Infarct Mortality and Heart Failure

Metabolic Reprogramming in Cardiovascular Diseases